Traditional Chinese Medicine-Based Network Pharmacology Could Lead to New Multicompound Drug Discovery

被引:76
作者
Li, Jian [2 ]
Lu, Cheng [1 ]
Jiang, Miao [1 ]
Niu, Xuyan [1 ]
Guo, Hongtao [1 ]
Li, Li [1 ]
Bian, Zhaoxiang [3 ]
Lin, Na [4 ]
Lu, Aiping [1 ]
机构
[1] China Acad Chinese Med Sci, Inst Basic Res Clin Med, Beijing 100700, Peoples R China
[2] Beijing Univ Chinese Med, Sch Basic Med Sci, Beijing 100029, Peoples R China
[3] Hong Kong Baptist Univ, Sch Chinese Med, Kowloon, Hong Kong, Peoples R China
[4] China Acad Chinese Med Sci, Inst Mat Med, Beijing 100700, Peoples R China
基金
美国国家科学基金会;
关键词
SYSTEMS BIOLOGY; PATTERN DIFFERENTIATION; RHEUMATOID-ARTHRITIS; DISEASE; MECHANISMS; POLYPILL; PUBCHEM; COLD;
D O I
10.1155/2012/149762
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Current strategies for drug discovery have reached a bottleneck where the paradigm is generally "one gene, one drug, one disease." However, using holistic and systemic views, network pharmacology may be the next paradigmin drug discovery. Based on network pharmacology, a combinational drug with two or more compounds could offer beneficial synergistic effects for complex diseases. Interestingly, traditional chinese medicine (TCM) has been practicing holistic views for over 3,000 years, and its distinguished feature is using herbal formulas to treat diseases based on the unique pattern classification. Though TCM herbal formulas are acknowledged as a great source for drug discovery, no drug discovery strategies compatible with the multidimensional complexities of TCM herbal formulas have been developed. In this paper, we highlighted some novel paradigms in TCM-based network pharmacology and new drug discovery. A multiple compound drug can be discovered by merging herbal formula-based pharmacological networks with TCM pattern-based disease molecular networks. Herbal formulas would be a source for multiple compound drug candidates, and the TCM pattern in the disease would be an indication for a new drug.
引用
收藏
页数:11
相关论文
共 57 条
[1]   Estimating the cost of new drug development: Is it really $802 million? [J].
Adams, CP ;
Brantner, VV .
HEALTH AFFAIRS, 2006, 25 (02) :420-428
[2]   Drug repositioning: Identifying and developing new uses for existing drugs [J].
Ashburn, TT ;
Thor, KB .
NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (08) :673-683
[3]   A Polypill for All? Critical Review of the Polypill Literature for Primary Prevention of Cardiovascular Disease and Stroke [J].
Carey, Katherine M. ;
Comee, Morgan R. ;
Donovan, Jennifer L. ;
Kanaan, Abir .
ANNALS OF PHARMACOTHERAPY, 2012, 46 (05) :688-695
[4]   PubChem as a Source of Polypharmacology [J].
Chen, Bin ;
Wild, David ;
Guha, Rajarshi .
JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2009, 49 (09) :2044-2055
[5]  
Chen G., 2012, EVID-BASED COMPL ALT, V2012
[6]   Prediction of the Mechanisms of Salvia Miltiorrhiza Against Atherosclerosis Using Text Mining and Network-Based Analysis [J].
Chen, Gao ;
Lu, Ai-ping .
JOURNAL OF ALGORITHMS & COMPUTATIONAL TECHNOLOGY, 2011, 5 (01) :139-144
[7]   A network-based analysis of traditional Chinese medicine cold and hot patterns in rheumatoid arthritis [J].
Chen, Gao ;
Lu, Cheng ;
Zha, Qinglin ;
Xiao, Cheng ;
Xu, Shijie ;
Ju, Dahong ;
Zhou, Youwen ;
Jia, Wei ;
Lu, Aiping .
COMPLEMENTARY THERAPIES IN MEDICINE, 2012, 20 (1-2) :23-30
[8]   Metabonomic study on the biochemical profiles of a hydrocortisone-induced animal model [J].
Chen, MJ ;
Zhao, LP ;
Jia, W .
JOURNAL OF PROTEOME RESEARCH, 2005, 4 (06) :2391-2396
[9]  
Chen YZ, 2001, PROTEINS, V43, P217, DOI 10.1002/1097-0134(20010501)43:2<217::AID-PROT1032>3.0.CO
[10]  
2-G